Morgan Stanley Maintains Overweight on Eikon Therapeutics, Lowers Price Target to $30
Benzinga Newsdesk 35 minutes ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Morgan Stanley analyst Sean Laaman maintains Eikon Therapeutics (NASDAQ:EIKN) with a Overweight and lowers the price target from $32 to $30.
Morgan Stanley analyst Sean Laaman maintains Eikon Therapeutics (NASDAQ:EIKN) with a Overweight and lowers the price target from $32 to $30.
